Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes

Inclusion Criteria

• •1. Histologically proven sarcoidosis from any site (noncaseating granulomas without other causes).
• •2. Diagnosis of active sarcoidosis (Sec. 5.5.4.t) clinical stage II by Chest X-ray (CXR).
• •3. Forced Vital Capacity (FVC) \>45% and Diffusing Capacity for Carbon Monoxide (DLCO) \>50% of predicted values.
• •4. Evidence of active sarcoidosis (see criteria above)
• •5. Able and willing to complete all study procedures (e.g., bronchoscopy, post-drug surveillance)
• •6. Age: 18+ years old (prevalence greatest in young adults; pediatric maraviroc safety not established).
• •7. Not on immunosuppression for sarcoidosis at the time of recruitment, (e.g., steroids, tumor necrosis factor alpha (TNF-a) blockade)
• •8. Liver function (transaminases, bilirubin), coagulation (International Normalized Ratio (INR), partial thromboplastin time (PTT), platelet count), blood urea nitrogen (BUN), creatinine, and white blood count (WBC) within normal limits.
• •9. If female: negative pregnancy test, agreement to use reliable contraception if of childbearing potential 30 days prior and for 30 days after study completion (drug safety during pregnancy not established).
• •10. Negative HIV and HBsAg tests